Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 14;11(12):e008067. doi: 10.1136/jitc-2023-008067

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Clinical evaluations. Serum PSA and PAP values were collected from all individuals prior to treatment (for PSA), over the course of treatment, and in the 1-year period off treatment. (A) Shown are the best percentage changes in serum PSA from day 1. Also shown are the individual plots over time of % change in serum PSA (B) or serum PAP (C) from the value obtained on day 1. (D) PSA doubling times for each patient were calculated from the values available up to 1 year prior to treatment, during the 1 year on treatment, and for the 1 year off treatment. (E) Fold change in PSA doubling time from pretreatment to on-treatment is displayed for each patient with symbols representing which patients developed an ELISPOT response at any post-treatment time point to PAP, which patients developed an immune-related adverse event (irAE), and which patients demonstrated an increase in serum CXCL9 at week 4 of treatment. (F) Shown is the time to radiographic progression. PAP, prostatic acid phosphatase; PSP, prostate-specific antigen.